In parallel, we administered a vesicular nucleotide transporter inhibitor (VNUTi), which reduces vesicular ATP release and thereby decreases eAdo production, as a positive control for both eAdo reduction and steatosis improvement (Figure 3a) [4]. Here, SLC17A9 is linked to steatosis.